Edition:
India

Morphosys And Vivoryon Therapeutics Enter Agreement On Small Molecule Inhibitors Of CD47-SIRP Alpha Signaling In Immuno-Oncology


Tuesday, 9 Jul 2019 

July 8 (Reuters) - Morphosys AG ::DGAP-NEWS: MORPHOSYS AND VIVORYON THERAPEUTICS ENTER AGREEMENT ON SMALL MOLECULE INHIBITORS OF CD47-SIRP ALPHA SIGNALING IN IMMUNO-ONCOLOGY.MORPHOSYS-IN EXCHANGE,CO COMMITTED TO INVESTING UP TO EUR 15 MILLION IN MINORITY STAKE IN VIVORYON AS PART OF A CAPITAL RAISE PLANNED FOR LATER THIS YEAR.MORPHOSYS -CO & VIVORYON THERAPEUTICS ENTERED DEAL UNDER WHICH CO OBTAINED EXCLUSIVE OPTION TO LICENSE VIVORYON'S SMALL MOLECULE QPCTL INHIBITORS IN FIELD OF ONCOLOGY.MORPHOSYS WILL CONDUCT PRECLINICAL VALIDATION EXPERIMENTS ON VIVORYON'S FAMILY OF QPCTL INHIBITORS.MORPHOSYS - IF CO CHOOSES TO EXERCISE OPTION, VIVORYON THERAPEUTICS WILL RECEIVE AN OPTION FEE, AND IS ELIGIBLE FOR MILESTONE PAYMENTS AND ROYALTIES. 

Company Quote

99.8
1.45 +1.47%
15 Oct 2019